Lactoferrin benefits

Lactoferrin is among the more heavily studied proteins in food science and among the less heavily tested in large human trials. The benefits claimed for it on supplement labels and health sites far outrun the second list. This page sets the two side by side.

Each claim below has its own page, and each page states its grade before any prose. The grade comes from the best available evidence, not the most recent study and not the most favorable one. The full scale, and the ledger of every graded claim, sits on the lactoferrin overview.

Where human trials support a benefit

The strongest human case concerns iron deficiency anemia in pregnancy. A meta-analysis of four randomized trials, 600 women in all, compared oral bovine lactoferrin with ferrous iron. Hemoglobin rose slightly more on lactoferrin (mean difference 0.77 g/dL, 95% CI 0.04 to 1.55), and digestive side effects were less frequent. The lower bound of that interval barely clears zero, so the grade is Supported rather than Established. The iron deficiency anemia page sets out the subgroup detail.

A second claim has pooled trial data behind it but no page on this site yet. Two meta-analyses published in 2009 examined lactoferrin added to standard Helicobacter pylori eradication therapy. One pooled five randomized trials with 682 participants and found an odds ratio for eradication of 2.22 (95% CI 1.44 to 3.44). Its authors described the evidence as limited. The other pooled nine trials with 1,343 participants. It reported eradication in 86.6% of those given lactoferrin against 74.4% without, and fewer side effects. The two reviews draw on overlapping trials, and some of those trials compared lactoferrin with no treatment rather than with placebo.

Where large trials found no effect

Two claims have been tested in randomized trials sized in advance to detect the effect, and both failed.

Small trials had suggested that bovine lactoferrin prevented infection in very preterm infants. The ELFIN trial randomized 2,203 of them. Late-onset infection occurred in 316 of 1,093 infants on lactoferrin and 334 of 1,089 on placebo (adjusted risk ratio 0.95, 95% CI 0.86 to 1.04). The preterm infant page covers why that result outranks the earlier ones.

COVID-19 followed a similar path. Four randomized trials, 553 participants in total, tested lactoferrin for prevention, for hospital treatment and for long COVID. In the largest, a blinded trial of 218 hospitalized adults, the risk ratio for death or intensive care admission was 1.06 (95% CI 0.63 to 1.79). The COVID-19 page reports all four.

Where the evidence is laboratory work

Lactoferrin's antibacterial activity is well documented in culture. It binds the iron that bacteria need, and part of the molecule disrupts bacterial membranes directly. That work is sound. It is graded Laboratory only because culture conditions differ from a human gut, and because the clinical trials that followed it, in preterm infants and in COVID-19, did not find an effect. The antibacterial action page explains both mechanisms.

Claims about immune support, gut health and skin have not been graded here yet. Each will get its own page once the primary literature behind it has been read.

Benefits and harms

A benefit only means something next to the harms. Supplemental lactoferrin comes from cow's milk, which rules it out for people with a milk protein allergy, and most trials are too small to detect rare adverse effects. The safety page reports what trials recorded.

Every graded claim